New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancerPRNewsWire • 10/25/26
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PRNewsWire • 10/24/26
Eli Lilly's Fast Growth Hasn't Slowed Its Progress As Sustainability LeaderInvestors Business Daily • 10/23/26
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan saysReuters • 10/23/26
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?The Motley Fool • 10/22/26
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to DeclineZacks Investment Research • 10/22/26
Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020PRNewsWire • 10/22/26
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?The Motley Fool • 10/22/26
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to KnowZacks Investment Research • 10/21/26
Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher24/7 Wall Street • 10/20/26
Tech Stocks Rebound From Heavy Losses Before Big Earnings Reports; Apple, Lilly Eye Buy PointsInvestors Business Daily • 10/19/26
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?Zacks Investment Research • 10/19/26
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are WinningMarketBeat • 10/19/26